WO1998043963A1 - Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses - Google Patents
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses Download PDFInfo
- Publication number
- WO1998043963A1 WO1998043963A1 PCT/US1998/006365 US9806365W WO9843963A1 WO 1998043963 A1 WO1998043963 A1 WO 1998043963A1 US 9806365 W US9806365 W US 9806365W WO 9843963 A1 WO9843963 A1 WO 9843963A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- benzenesulfonyl
- group
- hydroxy
- amino
- Prior art date
Links
- 0 C(C1)*11C2C1CCC2 Chemical compound C(C1)*11C2C1CCC2 0.000 description 6
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
- C07D213/34—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to compounds that inhibit metalloproteinases, particularly matrix metalloproteinases and tumor necrosis factor- ⁇ convertase, and their pharmaceutically acceptable salts and pharmaceutically acceptable prodrugs.
- the invention further relates to the uses of these compounds, salts and prodrugs for the therapeutic treatment of humans or animals.
- MMPs Matrix metalloproteinases
- collagenases include collagenases, gelatinases, matrilysin, and stromelysins, which are involved in the degradation and remodelling of connective tissues.
- These enzymes are found in a number of cell types that are found in or associated with connective tissue, such as fibroblasts, monocytes, macrophages, endothelial cells and metastatic tumor cells. They also share a number of properties, including zinc and calcium dependence, secretion as zymogens, and 40-50% amino acid sequence homology.
- Matrix metalloproteinases degrade the protein components of the extracellular matrix, i.e. the protein components found in the linings of joints, interstitial connective tissue, basement membranes, cartilage and the like. These proteins include collagen, proteoglycan, fibronectin and lamanin.
- Collagen is the major structural protein of mammalian tissue, comprising one- third of the total protein in mammalian organisms, and is an essential component of many matrix tissues, including cartilage, bone, tendons and skin.
- Interstitial collagenases catalyze the initial (rate-limiting) cleavage of native collagen types I, II, III and X. These enzymes cleave collagen into two fragments which spontaneously denature at physiological temperature. Denaturation of collagen involves conversion of the rigidly coiled helix to a random coil referred to as gelatin. These gelatin (denatured collagen) fragments are then subject to further cleavage and degradation by less specific enzymes. The net result of collagenase cleavage is thus the loss of structural integrity in the matrix tissue (collagen collapse), an essentially irreversible process.
- the gelatinases include two distinct yet highly related enzymes: a 72- kiloDalton (kDa) enzyme and a 92-kiloDalton enzyme.
- the former is released by fibroblasts while the latter is released by mononuclear phagocytes, neutrophils, corneal epithelial cells, tumor cells, cytotrophoblasts and keratinocytes.
- Both enzymes degrade gelatins (denatured collagens), collagen types IV (basement membrane) and V, fibronectins (high molecular weight multifunctional glycoproteins found in soft connective tissue and basement membranes) and insoluble elastin (highly cross-linked hydrophobic proteins found in load bearing fibers of mammalian connective tissue).
- Stromelysins (1 and 2) cleave a broad range of matrix substrates, including lamanin, fibronectins, proteoglycans and collagen types IV and IX (non-helical).
- Matrilysin (putative metalloproteinase or PUMP) also degrades a wide variety of matrix substrates, including proteoglycans, gelatins, fibronectins, elastins and lamanin. Matrilysin has been found in mononuclear phagocytes, rat uterine explants and tumor cells.
- a number of pathological disease conditions include arthritis (e.g., rheumatoid arthritis and osteoarthritis), periodontal disease, aberrant angiogenesis, tumor metastasis and invasion, tissue ulceration (e.g., corneal ulceration, gastric ulceration or epidermal ulceration), bone disease, HIV-infection and complications from diabetes.
- arthritis e.g., rheumatoid arthritis and osteoarthritis
- periodontal disease e.g., rheumatoid arthritis and osteoarthritis
- aberrant angiogenesis e.g., tumor metastasis and invasion
- tissue ulceration e.g., corneal ulceration, gastric ulceration or epidermal ulceration
- bone disease e.g., HIV-infection and complications from diabetes.
- Matrix metalloproteinase inhibitors are also the subject of numerous patents and patent applications, including: U.S. Patent No. 5,189,178; U.S. Patent No. 5,183,900; U.S. Patent No. 5,506,242; U.S. Patent No. 5,552,419; U.S. Patent No. 5,455,258; European Patent Application No. 0 438 223; European Patent Application No. 0 276 436; WIPO International Publication No. WO 92/21360; WIPO International Publication No. WO 92/06966; WIPO International Publication No. WO 92/09563; WIPO International Publication No. WO 96/00214; WIPO International Publication No. 95/35276; WIPO International Publication No. WO 96/27583, and WIPO International Publication No. WO 96/33172, the disclosures of each of which are incorporated herein by reference.
- Tumor necrosis factor-** (“TNF- ⁇ ”) is a cytokine which is produced as a 28- kDa precursor and released in an active 17-kDa form. This active form can mediate a large number of deleterious effects in vivo, including inflammation, fever, cardiovascular effects, haemorrhage, coagulation and acute phase responses, similar to those seen during acute infections and shock states. Chronic administration of TNF- ⁇ can cause cachexia and anorexia; accumulation of excess of TNF- ⁇ can be fatal.
- TNF- ⁇ convertase is a metalloproteinase involved in the biosynthesis of TNF- ⁇ . Inhibition of TNF- ⁇ convertase inhibits production of TNF- ⁇ .
- the present invention is therefore directed to certain compounds that inhibit metalloproteinases, such as MMPs and TNF- ⁇ convertase, their pharmaceutically acceptable prodrugs, salts and solvates, pharmaceutical compositions containing the same and methods of using the same, as well as to method and intermediates useful in their preparation. Additional features and advantages of the invention will be set forth in the description which follows, and in part will be apparent from the description or may be learned from practice of the invention.
- Y is O or S;
- Ar is an aryl group or a heteroaryl group;
- R is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or -C OJR ⁇ wherein R is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or NR 2 R 3 , wherein R 2 and R 3 independently are hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group; and
- X is -NH-OH or -OH, or a pharmaceutically acceptable prodrug, salt or solvate thereof.
- the present invention is also directed to a pharmaceutical composition
- a pharmaceutical composition comprising (a) a therapeutically effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable prodrug, salt or solvate thereof; and (b) a pharmaceutically acceptable carrier, diluent, vehicle or excipient.
- the present invention is further directed to a method of treating a mammalian disease condition mediated by metalloproteinase activity which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable prodrug, salt or solvate thereof.
- the present invention is directed to a method of treating tumor growth, invasion or metastasis, osteoarthritis, rheumatoid arthritis, osteoporosis, periodontitis, gingivitis, chronic dermal wounds, corneal ulceration, degenerative skin disorders, multiple sclerosis, stroke, atherosclerosis, glomerular disease, Alzheimer's disease, or a disease condition characterized by unwanted angiogenesis, such as diabetic retinopathy, macular degeneration, angiofibromas, or hemangiomas.
- the present invention is still further directed to a method of inhibiting the activity of a metalloproteinase that comprises contacting the metalloproteinase with an effective amount of a compound of formula (I) or a pharmaceutically acceptable prodrug, salt or solvate thereof.
- alkyl group is intended to mean a straight or branched chain monovalent radical of saturated and/or unsaturated carbon atoms and hydrogen atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, ethenyl, pentenyl, butenyi, propenyl, ethynyl, butynyl, propynyl, pentynyl, hexynyl, and the like, which may be unsubstituted (i.e., containing only carbon and hydrogen) or substituted by one or more suitable substituents as defined below.
- O-alkyl group or "alkoxy group” is intended to mean an oxygen bonded to an alkyl group, wherein the alkyl group is as defined above.
- a "cycloalkyl group” is intended to mean a non-aromatic, monovalent monocyciic, bicyclic, or tricyclic radical containing 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, or 14 carbon ring atoms, each of which may be saturated or unsaturated, and which may be unsubstituted or substituted by one or more suitable substituents as defined below, and to which may be fused one or more heterocycloalkyl groups, aryl groups, or heteroaryl groups, which themselves may be unsubstituted or substituted by one or more suitable substituents.
- cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1.]heptyl, bicyclo[2.2.1.]hept-2-en-5- yl, bicyclo[2.2.2]octyl, bicyclo[3.2.1.]nonyl, bicyclo[4.3.0]nonyl, bicyclo[4.4.0]decyl, indan-1-yl, indan-2-yl, tetralin-1-yl, tetralin-2-yl, adamantyl, and the like.
- a “heterocycloalkyl group” is intended to mean a non-aromatic, monovalent monocyciic, bicyclic, or tricyclic radical, which is saturated or unsaturated, containing 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, or 18 ring atoms, and which includes 1 , 2, 3, 4, or 5 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the radical is unsubstituted or substituted by one or more suitable substituents as defined below, and to which may be fused one or more cycloalkyl groups, aryl groups, or heteroaryl groups, which themselves may be unsubstituted or substituted by one or more suitable substituents.
- heterocycloalkyl groups include, but are not limited to, azetidinyl, pyrrolidyl, piperidyl, piperazinyl, morpholinyl, tetrahydro-2H-1 ,4-thiazinyl, tetrahydrofuryl, dihydrofuryl, tetrahydropyranyi, dihydropyranyl, 1 ,3-dioxolanyl, 1 ,3-dioxanyl, 1 ,4-dioxanyl, 1 ,3-oxathiolanyl, 1 ,3- oxathianyl, 1 ,3-dithianyl, azabicylo[3.2.1]octyl, azabicylo[3.3.1]nonyl, azabicylo[4.3.0]nonyl, oxabicylo[2.2.1]heptyl, 1 ,5,9-triazacycl
- aryl group is intended to mean an aromatic, monovalent monocyciic, bicyclic, or tricyclic radical containing 6, 10, 14, or 18 carbon ring atoms, which may be unsubstituted or substituted by one or more suitable substituents as defined below, and to which may be fused one or more cycloalkyl groups, heterocycloalkyl groups, or heteroaryl groups, which themselves may be unsubstituted or substituted by one or more suitable substituents.
- aryl groups include, but are not limited to, phenyl, naphthyl, fluoren-2-yl, indan-5-yl, and the like.
- heteroaryl group is intended to mean an aromatic monovalent monocyciic, bicyclic, or tricyclic radical containing 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, or 18 ring atoms, including 1 , 2, 3, 4, or 5 heteroatoms selected from nitrogen, oxygen and sulfur, which may be unsubstituted or substituted by one or more suitable substituents as defined below, and to which may be fused one or more cycloalkyl groups, heterocycloalkyl groups, or aryl groups, which themselves may be unsubstituted or substituted by one or more suitable substituents.
- heteroaryl groups include, but are not limited to, pyrrolyl, imidazoiyl, pyrazolyl, furyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyrazinyl, pyridyl, pyrimidyl, pyridazinyl, indolyl, isoindolyl, benzimidazolyl, benzofuryl, isobenzofuryl, benzothienyl, quinolyl, isoquinolyl, phthalazinyl, carbazolyl, purinyl, pteridinyl, acridinyl, phenanthrolinyl, phenoxazinyl, phenothiazinyl, and the like.
- acyl group is intended to mean a -C(0)-R 5 - radical, wherein R 5 is any suitable substituent as defined below.
- a “sulfonyl group” is intended to mean a -S(0)(0)-R 5 - radical, wherein R 5 is any suitable substituent as defined below.
- suitable substituent is intended to mean any of the substituents recognizable to those skilled in the art as not adversely affecting the inhibitory activity of the inventive compounds.
- suitable substituents include, but are not limited to, oxo groups, alkyl groups, hydroxy groups, halo groups, cyano groups, nitro groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, trialkylsilyl groups, groups of formula (A)
- R a is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, groups of formula (B)
- R a is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, groups of formula (C)
- R b and R c are independently hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, groups of formula (D)
- R d is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, a hydroxy group, an alkoxy group, an amino group, an alkylamino group, a dialkylamino group, or an acylamino group
- R e is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an amino group, an alkylamino group, or a dialkylamino group, groups of formula (E)
- R f is an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, groups of formula (F)
- R g and R h are independently hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, groups of formula (G)
- R is an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or a group of formula (A), formula (B), formula (C), formula (H) (defined below), or formula (K) (defined below), groups of formula (H)
- R t is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, a hydroxy group, an alkoxy group, an amino group, or a group of formula (A), formula (B), formula (C) or formula (D); and wherein R k is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or a group of formula (A), formula (B), formula (C), formula (D), formula (E), or formula (F), groups of formula (J) wherein R, is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or a group of formula (C), and groups of formula (K)
- R m and R n are independently an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, a hydroxy group, an alkoxy group, an amino group, an alkylamino group, or a dialkylamino group.
- suitable organic moiety is intended to mean any organic moiety recognizable to those skilled in the art as not adversely affecting the inhibitory activity of the inventive compounds.
- suitable organic moieties include, but are not limited to oxo groups, alkyl groups, hydroxy groups, halo groups, cyano groups, nitro groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, trialkylsilyl groups, and groups of formulas (A), (B), (C), (D), (E), (F), (G), (H), (J), and (K), as defined above.
- a "hydroxy group” is intended to mean the radical -OH.
- a "cyano group” is intended to mean the radical -C ⁇ N.
- a "nitro group” is intended to mean the radical -N0 2 .
- a "trialkylsilyl group” is intended to mean the radical -SiR p R q R s , where R p , R q , and R s are each independently an alkyl group.
- a “carboxy group” is intended to mean a group of formula (B) wherein R a is hydrogen.
- alkoxycarbonyl group is intended to mean a group of formula (B) wherein R a is an alkyl group as defined above.
- a “carbamoyl group” is intended to mean a group of formula (C) wherein R b and R c are both hydrogen.
- amino group is intended to mean the radical -NH 2 .
- alkylamino group is intended to mean the radical -NHR U , wherein R u is an alkyl group as defined above.
- a "dialkylamino group” is intended to mean the radical -NR U R V , wherein R u and R v , which are the same or different, are each an alkyl group as defined above.
- a "pharmaceutically acceptable prodrug” is intended to mean a compound that is converted under physiological conditions or by soivolysis to a compound of the formula I.
- a "pharmaceutically acceptable solvate” is intended to mean a solvate that retains the biological effectiveness and properties of the biologically active components of compounds of formula I.
- Examples of pharmaceutically acceptable solvates include, but are not limited to, compounds of formula I in combination with water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, or ethanolamine.
- inventive compounds may exist in different forms, such as stable and metastable crystalline forms and isotropic and amorphous forms, all of which are intended to be within the scope of the present invention.
- a “pharmaceutically acceptable salt” is intended to mean those salts that retain the biological effectiveness and properties of the free acids and bases and that are not biologically or otherwise undesirable.
- Examples of pharmaceutically acceptable salts include, but are not limited to, sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1 ,4-dioates, hexyne-1 ,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxyenzoates, phthalates, sulfonates, xylenesulfonates,
- the desired salt may be prepared by any suitable method known to the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosidyl acids such as glucuronic acid and galacturonic acid, alpha-hydroxy acids such as citric acid and tartaric acid, amino acids such as aspartic acid and glutamic acid, aromatic acids such as benzoic acid and cinnamic acid, sulfonic acids such a p-toluenesulfonic acid or ethanesulfonic acid, or the like.
- an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,
- the desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal or alkaline earth metal hydroxide or the like.
- an inorganic or organic base such as an amine (primary, secondary or tertiary), an alkali metal or alkaline earth metal hydroxide or the like.
- suitable salts include organic salts derived from amino acids such as glycine and arginine, ammonia, primary, secondary and tertiary amines, and cyclic amines such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
- inventive compounds may exist as single stereoisomers, racemates and/or mixtures of enantiomers and/or diastereomers. All such single stereoisomers, racemates and mixtures thereof are intended to be within the scope of the present invention.
- inventive compounds, and prodrugs, salts and solvates thereof have the formula la:
- an optically pure compound having one chiral center is one that consists essentially of one of the two possible enantiomers (i.e., is enantiomerically pure), and an optically pure compound having more than one chiral center is one that is both diastereomerically pure and enantiomerically pure.
- the compounds of the present invention are used in a form that is at least 90% optically pure, that is, a form that contains at least 90% of a single isomer (80% enantiomeric excess ("e.e.") or diastereomeric excess (“d.e.”)), more preferably at least 95% (90% e.e. or d.e.), even more preferably at least 97.5% (95% e.e. or d.e.), and most preferably at least 99% (98% e.e. or d.e.).
- Ar is an aryl group substituted with a suitable substitutent, as defined above, in the position para to the Y moiety.
- the suitable substituent is a halogen, an alkyl group, an O-alkyl group, an aryl group, a heteroaryl group, or an S- alkyl group.
- R is an alkyl group, preferably the alkyl group -(CH 3 ) 2 -S-alkyl, and still more preferably the alkyl group -C(CH 3 ) 2 -S-CH 2 -heteroaryl.
- the present invention is further directed to methods of inhibiting metalloproteinase activity, for example in mammalian tissue, by administering a compound of the formula I, or a pharmaceutically acceptable prodrug, salt or solvate thereof.
- the activity of the inventive compounds as inhibitors of metalloproteinases, such as MMPs (including stromelysins, collagenases, gelatinases and/or matrilysin) and/or TNF- « convertase may be measured by any of the methods available to those skilled in the art, including in vivo and/or in vitro assays. Examples of suitable assays for activity measurements include those described in Anal. Biochem., vol. 147, p. 437 (1985), Anal. Biochem., vol. 180, p. 110 (1989), FEBS, vol. 96, p. 263 (1992) and European Patent Application No. 0 606 046.
- Administration of the compounds of the formula I, or their pharmaceutically acceptable prodrugs, salts or solvates may be performed according to any of the accepted modes of administration available to those skilled in the art.
- suitable modes of administration include oral, nasal, parenteral, topical, transdermal and rectal.
- the mode of administration is oral.
- the inventive compounds of the formula I, or their pharmaceutically acceptable prodrugs, salts or solvates may be administered as a pharmaceutical composition in any suitable pharmaceutical form recognizable to the skilled artisan. Suitable pharmaceutical forms include, but are not limited to, solid, semisolid, liquid or lyophilized formulations, such as tablets, powders, capsules, suppositories, suspensions and aerosols.
- the pharmaceutical form is a tablet or capsule for oral administration.
- the pharmaceutical composition may also include suitable excipients, diluents, vehicles and carriers as well as other pharmaceutically active agents, depending upon the intended use.
- compositions may be prepared following conventional techniques of the pharmaceutical chemist involving steps such as mixing, granulating and compressing when necessary for tablet forms, or mixing, filling, and dissolving the ingredients as appropriate, to give the desired products for oral, parenteral, topical, intravaginal, intranasal, intrabronchial, intraocular, intraaural and/or rectal administration.
- steps such as mixing, granulating and compressing when necessary for tablet forms, or mixing, filling, and dissolving the ingredients as appropriate, to give the desired products for oral, parenteral, topical, intravaginal, intranasal, intrabronchial, intraocular, intraaural and/or rectal administration.
- steps such as mixing, granulating and compressing when necessary for tablet forms, or mixing, filling, and dissolving the ingredients as appropriate, to give the desired products for oral, parenteral, topical, intravaginal, intranasal, intrabronchial, intraocular, intraaural and/or rectal administration.
- Solid or liquid pharmaceutically acceptable carriers, diluents, vehicles or excipients may be employed in the pharmaceutical compositions.
- Illustrative solid carriers include starch, lactose, calcium sulphate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate and stearic acid.
- Illustrative liquid carriers include syrup, peanut oil, olive oil, saline solution and water.
- the carrier or diluent may include a suitable prolonged-release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
- the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid (e.g. solution), or a nonaqueous or aqueous liquid suspension.
- a dose of the pharmaceutical composition contains at least a therapeutically effective amount of the active compound (i.e., a compound of the formula I, or a pharmaceutically acceptable prodrug, salt or solvate thereof) and preferably is made up of one or more pharmaceutical dosage units.
- An exemplary dosage unit for a mammalian host contains an amount of from 0.1 milligram up to 500 milligrams of active compound per kilogram body weight of the host, preferably 0.1 to 200 milligrams, more preferably 50 milligrams or less, and even more preferably about 10 milligrams or less, per kilogram of the host weight.
- the selected dose may be administered to a mammal, for example, a human patient in need of treatment mediated by inhibition of metalloproteinase activity, by any known method of administrating the dose including: topically, for example, as an ointment or cream; orally; rectally, for example, as a suppository; parenterally by injection; or continuously by intravaginal, intranasal, intrabronchial, intraaural or intraocular infusion.
- the amount of the inventive compounds, salts, solvates and/or prodrugs to be administered will vary based upon a number of factors, including the specific metalloproteinase to be inhibited, the degree of inhibition desired, the characteristics of the mammalian tissue in which inhibition is desired, the metabolic stability and activity of the particular inventive compound employed, and the mode of administration.
- One skilled in the art may readily determine a suitable dosage according to methods known to the art.
- the amount of inventive compound of the formula I, or their pharmaceutically acceptable prodrugs, salts or solvates, administered ranges from 0.1 mg/kg body weight to 100 mg/kg body weight per day.
- inventive compounds and the salts, solvates, and prodrugs thereof, may be prepared by employing the techniques available in the art using starting materials that are readily available. Exemplary methods of preparing the inventive compounds are described below. In the following schemes, unless otherwise indicated, R, Ar and Y are as previously defined herein.
- hydroxamic acids of formula II i.e., compounds of Formula I, where X is NH-OH
- a suitable peptide coupling reagent for example, 1 ,1'-carbonyldimidazole, N-(dimethylaminopropyl)-N'-ethyl carbodiimide, benzotriazol- 1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate, or propane- phosphonic anhydride in an inert polar solvent, such as dimethylformamide.
- compounds of formula IV can be reacted with hydroxylamine in a suitable solvent mixture, such as THF/t-butanol/dichloromethane or water/dichloromethane, preferably at 0 °C, to give hydroxamic acids of formula II.
- a suitable solvent mixture such as THF/t-butanol/dichloromethane or water/dichloromethane, preferably at 0 °C
- Compounds of formula IV can generally be prepared, in a form directly useful for further reaction without isolation, by allowing carboxylic acids of formula 111 to react with thionyl chloride or oxalyl chloride, preferably in the presence of a catalytic amount of dimethylformamide, in dichoromethane solvent at -78 °C to room temperature.
- the coupling reactions described above may be carried out with compounds of formula III (or IV) and O-protected derivatives of hydroxylamine, where Pg is a protecting group, for example, benzyl, tert-butyl, t-butyldimethylsilyl, or t- butyldiphenylsilyl, to give compounds of formula V.
- Pg is a protecting group, for example, benzyl, tert-butyl, t-butyldimethylsilyl, or t- butyldiphenylsilyl
- Carboxylic acids III can be prepared as shown in Scheme 2 by reaction of ⁇ - amino acids with arylsulfonyl chlorides of formula VIII, under biphasic basic conditions as described, for example, in "The Chemistry of the Amino Acids", J.P. Greenstein and M. Winitz, Robert E. Krieger Publishing Company, 1984, p. 886-889.
- ⁇ -Amino acids are commercially-available, or can be prepared according to methods familiar to those skilled in the art.
- Carboxylic acids III can also prepared by reaction of ⁇ -amino acid derivatives where Pg is any suitable protecting group as described, for example, in "Protective Groups in Organic Synthesis", T.W. Greene and P. G. M. Wuts, Wiley-lnterscience 1991 , with aryl sulfonyl chlorides VIII to give sulfonamides VI under any of a variety of reaction conditions known to those skilled in the art for the sulfonylation of amines. Deprotection of VI to give the acids III can be carried out as appropriate to the protecting group Pg.
- amino acid side chain R or in the aryl group Ar may be readily effected at the stage of VI prior to the deprotection of VI to III.
- Amino acid derivatives VII are commercially available, or are prepared according to methods familiar to those skilled in the art.
- D-penicillamine Treatment of D-penicillamine with a molar equivalent of a trialkylchlorosilane, such as trimethylsiiyl chloride or dimethylthexylsilyl chloride, and a molar equivalent of a suitable base, such as 1 ,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or diisopropylethylamine, in suitable solvent, such as DMF, at approximately 25 °C for 1 to 6 hours can provide the silyl ester Vll-A.
- a trialkylchlorosilane such as trimethylsiiyl chloride or dimethylthexylsilyl chloride
- a suitable base such as 1 ,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or diisopropylethylamine
- suitable solvent such as DMF
- the solution of this ester Vll-A can be treated with an additional DBU (at least one molar equivalent) and an alkylating reagent R 5 -X, where R 5 is an alkyl group, preferably a CH 2 -heteroaryl group, to give the S-alkylated silyl ester VII- B.
- the resulting solution of Vll-B can be treated with the aryl sulfonyl chloride VIII to provide the sulfonamide silyl ester Vll-C.
- the silyl ester Vll-C undergoes hydrolysis to provide the desired acid lll-A.
- a suitable inert solvent such as 1 ,2- dichloroethane or dichloromethane
- X is further converted to the sulfonyl chloride VIII by reaction with, for example, oxalyl chloride or thionyl chloride and cataltyic DMF.
- excess chlorosulfonic acid is effective at converting IX directly to VIII via the intermediacy of X.
- Compounds of the formula IX are commercially-available, or may be readily prepared by those skilled in the art from commercially-available materials by the Ullman reaction.
- reaction mixture was poured into ice-pH 7 phosphate buffer (50mL), then extracted with EtOAc:Hexane (4:3) (3x150mL). The combined organic layers were washed with brine (75mL). The aqueous layer was extracted with EtOAc/Hexane(4:3) (150mL).
- Example 1(e) 4-(4-lodophenoxy)benzenesulfonyl chloride ⁇ Vlll-A: Z l ⁇ from 4- iodobiphenyl ether (supplier: Transworld): mp 85-88 °C.
- the remaining aqueous phase was extracted with tetrabutylammonium bromide (940 g) in dichloromethane (6L), adjusting the aqueous phase to pH 7 with 2M aq. sodium hydroxide as necessary.
- the extraction was repeated two more times and the combined organic layers were dried over magnesium sulfate, filtered, and concentrated.
- the residue was dissolved with 20% ethanol in ethyl acetate (8 L, dry), and hydrogen chloride gas added to achieve a pH of 1.
- the solid was filtered off, and the filter cake was rinsed with the precipitation solvent mixture (20% ethyanol in ethyl acetate, 2 L).
- Example 4 N-[4-(4-(Furan-3-yl)phenoxy)benzenesulfonyl]-S-[(pyrid-2- yl)methyl]-D-penicillamine.
- the mixture was heated at 80°C with vigorous stirring for 72 hours, cooled to room temperature, and partitioned between ehtyl acetate and AcOH/H 2 0 buffer (pH 3).
- the aqueous layer was adjusted to pH of 3 by adding AcOH, then extracted with EtOAc (2x70mL).
- the combined organic layers were washed with brine, dried over Na 2 S0 4 ,and concentrated.
- the residual yellow solid was chromatographed on silica gel, eluting first with CH 2 CI 2 then with 10% methanol in dichloromethane to elute the product fractions. After concentration of the product-containing fractions, the residue was triturated with hexane/t-butyl methyl ether, and the solid was collected by filtration.
- D-penicillamine methyl ester hydrochloride (0.250g., 1.25 mmoles) in DMF (4 mL) was added DBU (0.382 ml., 2.56 mmoles), followed by methyl iodide (0.081 ml., 1.31 mmoles). After 1 hour, the solution was partitioned between brine and ethyl acetate, and the organic layer was dried over sodium sulfate and concentrated.
- Example 8 Preparation of Compounds of Formula lll-A
- Example 9 Preparation of Compounds of Formula ll-A
- Examples 9(o) through 9(s) may be prepared in a similar fashion:
- Examples 10(a), 10(b), and 10(c) were prepared in a manner similar to that described in Example 9(a).
- the catalytic domain of human collagenase-1 was expressed as a fusion protein with ubiquitin in E. coli (see Gehring, E.R., J Biol. Chem., 1995, 270, 22507).
- the fibroblast collagenase-1 catalytic domain was released either by treatment with purified, active stromelysin-1 (1 :50 w/w ratio), which generated nearly 100% N-terminal Phe1 , or by autoprocessing the concentrated collagenase-1 fusion and then incubating at 37 °C for 1 hour. Final purification was completed using zinc chelate chromatography.
- the propeptide and catalytic domain of human collagenase-3 (Coll3) was expressed in E. coli as an N-terminal fusion protein with ubiquitin. After purification of the fusion from inclusion bodies, the catalytic domain was liberated by treatment with 2mM APMA at room temperature overnight. Final purification was completed using copper chelate chromatography.
- the catalytic domain of human stromelysin (Sin) was obtained by expression and purification of a C-ter minally truncated prostromelysin-1 from E. coli host BL21 (see Marcy et al. Biochem., 1991 , 30, 6476). The subsequent activation of the mature form (Sin) was completed with 2mM APMA for 1 hour at 37 °C, followed by separation using a sizing column.
- Human matrilysin (Matr) was expressed in E. coli as a fusion protein with ubiquitin. After purification of the matrilysin/ubiquitin fusion from inclusion bodies, the catalytic domain was liberated by treatment with 2mM APMA at 37 °C for 2 hours. Final purification was complete using copper chelate chromatography.
- the catalytic and fibronectin-like portion of human progelatinase A (GelA) was expressed as a fusion protein with ubiquitin in E. Coli . Assays were carried out on autocatalytically activated material.
- Assays were performed in assay buffer (50 mM Tricine pH 7.5, 200 mM sodium chloride, 10 mM calcium chloride, 0.5 mM zinc acetate containing 2% dimethyl sulfoxide (DMSO)) once the substrate and inhibitor were diluted into it. Stock solutions of inhibitors were prepared in 100% DMSO. Stock solutions of the substrate were prepared in 100% DMSO at a concentration of 6 mM.
- assay buffer 50 mM Tricine pH 7.5, 200 mM sodium chloride, 10 mM calcium chloride, 0.5 mM zinc acetate containing 2% dimethyl sulfoxide (DMSO)
- the assay method was based on the hydrolysis of MCA-Pro-Leu-Gly-Leu- DPA-Ala-Arg-NH 2 (American Peptide Co.) at 37 °C (see Knight, C.G. et al., FEBS, 1992, 296, 263-266).
- the fluorescence changes were monitored with a Perkin- Elmer LS-50B fluorimeter using an excitation wavelength of 328 nm and an emission wavelength of 393 nm.
- the substrate concentration used in the assays was 10 ⁇ M.
- the inhibitor was diluted into the assays from a solution in 100% DMSO, and controls substituted an equal volume of DMSO so that the final DMSO concentration from inhibitor and substrate dilution in all assays was 2%.
- the concentration of enzyme in the assay ranged from 60 pM for gelatinase A to 1.5 nM for stromelysin and is a function of the enzymes respective k ca ⁇ /K m for the MCA peptide substrate.
- K m for the MCA peptide substrate with the matrix metalloproteinases is quite high and exceeds its solubility under assay conditions. Consequently, the apparent K, (Ki, app ) was determined to describe the strength of inhibition. However, in this case, K, app would be essentially equal to K, since [S] «K m .
- K ⁇ app the concentration of the inhibitor was varied at a constant and low concentration of substrate and the steady-state rates of fluorescence change determined. In most cases absorptive quench due to the presence of ligand was not observed. For slow-binding inhibitors, onset of inhibition curves were collected for at least 45 minutes so that equilibrium was established.
- Example 9 The compound of Example 9 from WO 95/35276, N-hydroxy-2-(toluene-4- sulfonylamino)acetamide (compound 13 shown below in Table 2), was prepared and its Ki's against gelatinase A and Stromelysin were determined. Table 2 shows these results in comparison to the results obtained for representative preferred compounds from the present invention.
- the compounds of Examples 9d, 9e, and 9m are 3400 to 500,000 times more potent as inhibitors of stromelysin and gelatinase A than the composition of Example 13, not according to the invention.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP54194598A JP2001521504A (en) | 1997-04-01 | 1998-03-31 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their use as medicaments |
KR1019997009017A KR20010005940A (en) | 1997-04-01 | 1998-03-31 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
CA002285372A CA2285372A1 (en) | 1997-04-01 | 1998-03-31 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
BR9809062-3A BR9809062A (en) | 1997-04-01 | 1998-03-31 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
EP98914379A EP0973748A1 (en) | 1997-04-01 | 1998-03-31 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
AU68744/98A AU747280B2 (en) | 1997-04-01 | 1998-03-31 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82531897A | 1997-04-01 | 1997-04-01 | |
US08/825,318 | 1997-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998043963A1 true WO1998043963A1 (en) | 1998-10-08 |
Family
ID=25243697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/006365 WO1998043963A1 (en) | 1997-04-01 | 1998-03-31 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0973748A1 (en) |
JP (1) | JP2001521504A (en) |
KR (1) | KR20010005940A (en) |
AU (1) | AU747280B2 (en) |
BR (1) | BR9809062A (en) |
CA (1) | CA2285372A1 (en) |
NZ (1) | NZ338082A (en) |
WO (1) | WO1998043963A1 (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999006340A2 (en) * | 1997-07-31 | 1999-02-11 | The Procter & Gamble Company | Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors |
EP0930067A2 (en) * | 1997-12-19 | 1999-07-21 | Pfizer Products Inc. | Mmp inhibitors for the treatment of ocular angiogenesis |
US6075136A (en) * | 1998-02-17 | 2000-06-13 | Incyte Pharmaceuticals, Inc. | Prostate-associated serine protease |
EP1029541A4 (en) * | 1997-07-22 | 2000-08-23 | Shionogi & Co | Therapeutic or prophylactic agent for glomerulopathy |
US6197770B1 (en) | 1999-03-03 | 2001-03-06 | The Procter & Gamble Co. | Alkenyl- and alkynl-containing metalloprotease inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6277987B1 (en) | 1998-02-04 | 2001-08-21 | Novartis Ag | Sulfonylamino acid and sulfonylamino hydroxamic acid derivatives |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
US6358980B1 (en) | 1999-01-27 | 2002-03-19 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
US6492394B1 (en) | 1998-12-22 | 2002-12-10 | Syntex (U.S.A.) Llc | Sulfonamide hydroxamates |
US6566381B1 (en) | 1999-03-03 | 2003-05-20 | The Procter & Gamble Company | Hetero-substituted metalloprotease inhibitors |
US6696456B1 (en) * | 1999-10-14 | 2004-02-24 | The Procter & Gamble Company | Beta disubstituted metalloprotease inhibitors |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
EP1511488A2 (en) * | 2002-06-12 | 2005-03-09 | Exelixis, Inc. | Human adam-10 inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
US7282496B2 (en) | 2001-11-01 | 2007-10-16 | Wyeth Holdings Corporation | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
WO2008070579A2 (en) * | 2006-12-01 | 2008-06-12 | Loma Linda University Medical Center | Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration |
US7504537B2 (en) | 2001-12-27 | 2009-03-17 | Dainippon Sumitomo Pharma Co., Ltd. | Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient |
WO2020070239A1 (en) | 2018-10-04 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995035276A1 (en) * | 1994-06-22 | 1995-12-28 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
WO1996027583A1 (en) * | 1995-03-08 | 1996-09-12 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
EP0757984A1 (en) * | 1995-08-08 | 1997-02-12 | Ono Pharmaceutical Co., Ltd. | Hydroxamic acid derivatives useful for inhibiting gelatinase |
WO1997020824A1 (en) * | 1995-12-08 | 1997-06-12 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation |
WO1997027174A1 (en) * | 1996-01-23 | 1997-07-31 | Shionogi & Co., Ltd. | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
-
1998
- 1998-03-31 BR BR9809062-3A patent/BR9809062A/en not_active IP Right Cessation
- 1998-03-31 JP JP54194598A patent/JP2001521504A/en not_active Ceased
- 1998-03-31 WO PCT/US1998/006365 patent/WO1998043963A1/en not_active Application Discontinuation
- 1998-03-31 EP EP98914379A patent/EP0973748A1/en not_active Withdrawn
- 1998-03-31 NZ NZ338082A patent/NZ338082A/en unknown
- 1998-03-31 AU AU68744/98A patent/AU747280B2/en not_active Ceased
- 1998-03-31 CA CA002285372A patent/CA2285372A1/en not_active Abandoned
- 1998-03-31 KR KR1019997009017A patent/KR20010005940A/en not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995035276A1 (en) * | 1994-06-22 | 1995-12-28 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
WO1996027583A1 (en) * | 1995-03-08 | 1996-09-12 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
EP0757984A1 (en) * | 1995-08-08 | 1997-02-12 | Ono Pharmaceutical Co., Ltd. | Hydroxamic acid derivatives useful for inhibiting gelatinase |
WO1997020824A1 (en) * | 1995-12-08 | 1997-06-12 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation |
WO1997027174A1 (en) * | 1996-01-23 | 1997-07-31 | Shionogi & Co., Ltd. | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Week 9736, Derwent World Patents Index; AN 97-393586, XP002069234 * |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1029541A4 (en) * | 1997-07-22 | 2000-08-23 | Shionogi & Co | Therapeutic or prophylactic agent for glomerulopathy |
US6423729B1 (en) | 1997-07-22 | 2002-07-23 | Shionogi & Co., Ltd. | Therapeutic or prophylactic agent for glomerulopathy |
US6878739B2 (en) | 1997-07-22 | 2005-04-12 | Shionogi & Co., Ltd. | Composition for treating or preventing glomerulopathy |
EP1029541A1 (en) * | 1997-07-22 | 2000-08-23 | Shionogi & Co., Ltd. | Therapeutic or prophylactic agent for glomerulopathy |
WO1999006340A3 (en) * | 1997-07-31 | 1999-09-30 | Procter & Gamble | Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors |
US6218389B1 (en) | 1997-07-31 | 2001-04-17 | The Procter & Gamble Co. | Acyclic metalloprotease inhibitors |
WO1999006340A2 (en) * | 1997-07-31 | 1999-02-11 | The Procter & Gamble Company | Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors |
EP0930067A3 (en) * | 1997-12-19 | 1999-09-15 | Pfizer Products Inc. | MMP inhibitors for the treatment of ocular angiogenesis |
EP0930067A2 (en) * | 1997-12-19 | 1999-07-21 | Pfizer Products Inc. | Mmp inhibitors for the treatment of ocular angiogenesis |
US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
US6277987B1 (en) | 1998-02-04 | 2001-08-21 | Novartis Ag | Sulfonylamino acid and sulfonylamino hydroxamic acid derivatives |
US6075136A (en) * | 1998-02-17 | 2000-06-13 | Incyte Pharmaceuticals, Inc. | Prostate-associated serine protease |
US6844366B2 (en) | 1998-12-22 | 2005-01-18 | Syntex (U.S.A.) Llc | Sulfonamide hydroxamates |
US6787559B2 (en) | 1998-12-22 | 2004-09-07 | Syntex (U.S.A.) Llc. | Sulfonamide compounds |
US6492394B1 (en) | 1998-12-22 | 2002-12-10 | Syntex (U.S.A.) Llc | Sulfonamide hydroxamates |
US6716833B2 (en) | 1999-01-27 | 2004-04-06 | Wyeth Holdings Corporation | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6825354B2 (en) | 1999-01-27 | 2004-11-30 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and TACE inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
US6358980B1 (en) | 1999-01-27 | 2002-03-19 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6812227B2 (en) | 1999-01-27 | 2004-11-02 | Wyeth Holdings Corporation | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6566381B1 (en) | 1999-03-03 | 2003-05-20 | The Procter & Gamble Company | Hetero-substituted metalloprotease inhibitors |
US6762198B2 (en) | 1999-03-03 | 2004-07-13 | The Procter & Gamble Company | Dihetero-substituted metalloprotease inhibitors |
US6197770B1 (en) | 1999-03-03 | 2001-03-06 | The Procter & Gamble Co. | Alkenyl- and alkynl-containing metalloprotease inhibitors |
US6696456B1 (en) * | 1999-10-14 | 2004-02-24 | The Procter & Gamble Company | Beta disubstituted metalloprotease inhibitors |
US7282496B2 (en) | 2001-11-01 | 2007-10-16 | Wyeth Holdings Corporation | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US7504537B2 (en) | 2001-12-27 | 2009-03-17 | Dainippon Sumitomo Pharma Co., Ltd. | Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient |
EP1511488A2 (en) * | 2002-06-12 | 2005-03-09 | Exelixis, Inc. | Human adam-10 inhibitors |
EP1511488A4 (en) * | 2002-06-12 | 2008-11-19 | Exelixis Inc | Human adam-10 inhibitors |
US7629341B2 (en) | 2002-06-12 | 2009-12-08 | Symphony Evolution, Inc. | Human ADAM-10 inhibitors |
US7989661B2 (en) | 2002-06-12 | 2011-08-02 | Symphony Evolution, Inc. | Human ADAM-10 inhibitors |
EP2428509A1 (en) * | 2002-06-12 | 2012-03-14 | Symphony Evolution, Inc. | Human adam-10 inhibitors |
US7485667B2 (en) | 2002-12-23 | 2009-02-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
WO2008070579A2 (en) * | 2006-12-01 | 2008-06-12 | Loma Linda University Medical Center | Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration |
WO2008070579A3 (en) * | 2006-12-01 | 2009-03-19 | Univ Loma Linda Med | Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration |
WO2020070239A1 (en) | 2018-10-04 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Also Published As
Publication number | Publication date |
---|---|
EP0973748A1 (en) | 2000-01-26 |
NZ338082A (en) | 2000-06-23 |
KR20010005940A (en) | 2001-01-15 |
AU747280B2 (en) | 2002-05-09 |
CA2285372A1 (en) | 1998-10-08 |
BR9809062A (en) | 2000-08-01 |
JP2001521504A (en) | 2001-11-06 |
AU6874498A (en) | 1998-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU747280B2 (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses | |
US5985900A (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses | |
USH1992H1 (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their pharmaceutical uses | |
US6153757A (en) | Metalloproteinase inhibitors and intermediates useful for their preparation | |
US5753653A (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses | |
ES2236829T3 (en) | BETA-SULFONIL HYDROXAMIC ACIDS AS INHIBITORS OF THE METALOPROTEINS OF THE MATRIX. | |
AU725403B2 (en) | Thrombin inhibitors | |
US6765003B1 (en) | 3-Arylsulfonyl-2 (substituted methyl) propanoic acid derivatives as matrix metalloproteinase inhibitors | |
CA2484011A1 (en) | Cysteine protease inhibitors | |
CA2241414A1 (en) | Thiol derivatives with metallopeptidase inhibitory activity | |
JP2011525487A (en) | A novel heterocyclic carboxamide for use as a thrombin inhibitor | |
US6500948B1 (en) | Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof | |
MXPA99008995A (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses | |
AU763835B2 (en) | Heteroaryl succinamides and their use as metalloproteinase inhibitors | |
CN101932560B (en) | Inhibitors for matrix metalloproteinases, pharmaceutical compositions containing them and their uses | |
MXPA02006599A (en) | Nonpeptidyl inhibitors of vla4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 338082 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2285372 Country of ref document: CA Ref country code: CA Ref document number: 2285372 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 68744/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/008995 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 541945 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997009017 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998914379 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998914379 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997009017 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 68744/98 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019997009017 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998914379 Country of ref document: EP |